Abstract
Background Electrolyte imbalances are known to contribute to intestinal ileus. However, the direct impact of hypophosphatemia on post-operative ileus (POI) is unknown.
Objective To describe post-operative phosphate dynamics and if hypophosphatemia is associated with POI after a right colon resection.
Design Comparative retrospective cohort study
Settings High-volume tertiary referral center
Patients Patients who underwent right colon resection, which includes right hemicolectomies and ileocolic resections between 2020 and 2022.
Main Outcome Measures POI incidence, post-surgical phosphate dynamics, and post-operative phosphate deficit and recovery.
Results A total of 396 patients were reviewed, where 68% of resections were for inflammatory bowel disease. Patients had a mean return of bowel function on POD 3.78 ± 1.45. 17.4% of patients overall had POI. Serum phosphate was the most dynamic post-operative electrolyte, with statistically significant differences between POI and non-POI on POD 1, 3, and 7 (p < 0.05). Serum phosphate recovery in patients with POI was impaired at 0.11 mg/dL/day versus 0.17 mg/dL/day (p < 0.001). Patients with POI had a phosphate deficit that persisted beginning on POD 2, with statistically significant deficits on POD 3-5 (p < 0.01), as well as POD 7 (p < 0.001). On multivariate analysis, a phosphate deficit on POD 3 (ORadj 9.04, 95% CI 1.38-59.2), POD 5 (ORadj 7.05, 1.13-44.1), and POD 7 (ORadj 47.2, 2.98-749.4) were the only independent risk factors for POI.
Limitations Generalizability of these findings may be limited outside of right colon resections.
Conclusions We have established baseline phosphate dynamics in patients who undergo ileocolic anastomoses. We found POI was associated with a delayed serum phosphate recovery, as well as lower overall phosphate levels. Thus, a potential post-surgical window for intervention with timed phosphate repletion may have the potential to reduce post-operative ileus, need for nasogastric decompression, and ultimately decrease hospital length of stay.
Competing Interest Statement
PS serves as a consultant for Ethicon, Medtronic, Olympus, SafeHeal, Karl Storz, and Boston Scientific.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Mount Sinai Hospital IRB# STUDY-22-00711
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosure: PS serves as a consultant for Ethicon, Medtronic, Olympus, SafeHeal, Karl Storz, and Boston Scientific.
IRB: This study was approved by the Mount Sinai Hospital IRB# STUDY-22-00711
Data Availability
All data produced in the present study are available upon reasonable request to the authors
